Categories

-

Rising STD rate sparks online dating sites

February 28, 2007

When John got divorced after 12 years of marriage, he took a deep breath and launched into the dating scene.

“And wham, with my very first girlfriend, I caught herpes,” he says. “You feel betrayed and all of a sudden separated from the rest of the world. I thought at the time that the girl who gave it to me and I were the only people in the world who had it.”

But John and his date are far from alone. And the growing number of people in similar situations has created a new industry: Internet dating sites just for people with STDs. From stdmatch.netexternal link to datingwithherpes.comexternal link, Web sites abound for the infected who want to date the infected.

It’s not surprising once you see the numbers. One in four women is infected with genital herpes, and nearly one in five men according to the Centers for Disease Control and Prevention. And a study in this week’s Journal of the American Medical Association finds that one in four women has human papillomavirus, which can cause genital warts and cervical cancer.(Interactive: Test your STD knowledge)

Once John got over the initial shock of his diagnosis, one of the first things he did was go online.

“I went on Craig’s List and posted a note that said, ‘I live in Charlotte, North Carolina, and I’m a decent professional man, and I’ve ended up with this.’ Someone then contacted me and said, ‘Have you heard of Charlotteh?’”

Once John joined Charlotteh.comexternal link - part support group, part dating site for people with herpes - everything changed. “I would have been happy to have had just one person to unload everything I was feeling,” he says. “Instead I found more than 500.”

“Charlotteh” was started two years ago by Pam - who, like John, doesn’t want her last name used. She discovered she had herpes, and dating had become difficult.

“I’m 27, working on a Ph.D., own a second home, I have a master’s degree, but when I go into a relationship, I bring this with me, and that’s hard,” she says.

Even knowing when to tell a prospective boyfriend about herpes is tough. “It’s confusing, because you don’t know when the right time is to tell somebody. Should you be up front and get it over with or wait until the person develops feelings for you? It’s a big ethical problem.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

For Jennifer Nicholas, it was more than just an ethical problem. Once she told men she was dating about herpes, many ran in the opposite direction.

“One guy, I thought he was Mr. Perfect. But then when I told him that I had herpes, he said, ‘Forget my phone number, forget my address,’ and he blocked me from being able to message him on the computer,” she says.

Jennifer joined atlantahclub.comexternal link, another site for people with herpes. These sites immediately take several questions off the table. Members don’t have to worry about when to tell other members they have herpes, since everyone in the group does. And they don’t have to worry about spreading herpes, since the other members already have it.

Pam says at first, people are very nervous about joining, because it may be the first time they identify themselves as having herpes.

“People show up for their first support group meeting and sometimes they turn right around at the door because they don’t have the courage to come in,” said Pam. But then later, “I have people sending me thank you e-mails all the time. A guy came to a support group meeting and sent me flowers.”

Since many of the members have not come out to family and friends, a password is needed to get into the photo gallery showing pictures of social events and to receive any specific information about members.

A big part of STD Internet groups is social outings. One site, H2Ofriends.comexternal link, lists events for people with herpes in some 40 cities, from San Francisco, California, to Cedar Rapids, Iowa.

Some events attract hundreds of people. They look just like any other large party. “When we go on outings, we don’t put a sign up in the hallway saying, ‘Meeting of the Charlotte herpes club,’” Pam said, “Once we went to dinner and there were 30 of us and the hostess asked, ‘What’s the special occasion?’ My friend said, ‘We’re the Charlotte pottery club!’”

Posted by toshko under Herpes News | Comments (0)

Anti-Herpes Treatment Reduces HIV Levels In Women Infected With Both Viruses

February 27, 2007

Experts call for HSV control measures, including vaccine, to rank high on international HIV prevention and research agenda as exciting trial findings are published

Treating women who are infected with both the HSV-2 and HIV viruses with anti-herpes treatment can reduce the amount of HIV in the blood and genital secretions, according to the results of a trial published in the New England Journal of Medicine.

A collaborative group of scientists from the Centre Muraz (Burkina Faso), the University of Montpellier (France) and the London School of Hygiene & Tropical Medicine (UK) carried out the trial among women co-infected with the human immuno-deficiency virus (HIV) and the virus that causes genital herpes (HSV-2) in Burkina Faso. The results showed that having the herpes virus increased the replication of HIV, and also revealed that the quantity of HIV in the blood and in the vagina was reduced by continuous anti-herpes treatment over 3 months.

These findings open new avenues for the prevention of HIV transmission and for the management of patients co-infected by the two viruses.

In 2005, an estimated 4.1 million people were newly infected with HIV, mostly through heterosexual intercourse1. This alarming number of infections highlights the urgent need to intensify and expand proven prevention methods, and further, to identify and implement new methods of HIV prevention.

A number of observational studies have indicated that HSV-2 enhances the risk of HIV-1 acquisition by around three-fold2. HSV-2 infection may also increase HIV-1 infectiousness by disrupting the genital mucosa and increasing the levels of HIV in the genital tract3, allowing easier transmissibility of the virus. In addition, the HIV viral load in the blood of HIV-1 infected patients increases, at least temporarily, during episodes of HSV reactivation.

Lead author Dr. Nicolas Nagot, of the London School of Hygiene & Tropical Medicine (LSHTM), explains: ‘Behavioural interventions are not always successful, as knowledge does not necessarily translate into sexual behaviour change. Therefore, innovative methods that target the biological susceptibility of individuals to acquire or transmit HIV are also required. A number of options to prevent HIV transmission are currently being investigated, including the role of vaginal microbicides, pre-exposure HIV prophylaxis, male circumcision, and - in the future - an HIV vaccine.’

‘The results of the trial are striking’, he adds. ‘They show that valacyclovir significantly reduces the frequency and quantity of HIV detectable in genital secretions and, in addition, reduces the quantity of HIV in the plasma. As expected, there was also dramatic reduction in the detection of symptomatic and asymptomatic presence of HSV-2. The effects appeared to gradually increase over the 3 month follow-up period, with no sign of abating.’ These results indicate a new way to possibly reduce the sexual transmission of HIV from already infected individuals to their partners, since the frequency and quantity of HIV in the female genital tract are closely related to the transmission of the virus.

The findings will need to be confirmed by further research, and there is already a large ongoing trial that is measuring direct transmission of HIV between discordant couples in several sites worldwide.

Dr Philippe Mayaud, one of Dr Nagot’s colleagues at the LSHTM concludes: ‘Our results have important potential implications for public health and clinical practice, as HSV-2 control could become a new form of HIV prevention targeting HIV-infected individuals, as well as providing clinical benefits. Importantly, an HSV vaccine that would either prevent HSV infection or diminish the clinical and sub-clinical manifestations of HSV with a similar efficacy on HIV as HSV suppressive therapy, would represent a long-lasting form of HIV prevention. The development and evaluation of an HSV vaccine should rank high on the international research agenda.’

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

Gareth Thomas, UK Minister for International Development, whose department DFID has provided supplementary funding for the research, said: “These exciting initial findings demonstrate why research into reducing HIV/ AIDS transmission is such a vital element of the fight against the disease. The UK Government has pledged to spend £1.5 billion tackling HIV/AIDS in developing countries between 2005 and 2008. We will follow the next stages of this research with interest.”

###

For further information, please contact: Philippe Mayaud, Clinical Research Unit, Department of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT.

1. Herpes simplex virus type-2 (HSV-2), a sexually transmitted virus, is one of the most common pathogens worldwide4. HSV-2 is a lifelong infection and is found in nearly 80% of HIV-infected patients. Once acquired, the virus cycles between latency (hidden in nerves), asymptomatic genital excretion of the virus (’shedding’), and clinical reactivations that can produce painful ulcers in and around the genitalia. The herpes virus can be targeted by specific HSV-2 antiviral drugs such as acyclovir, valacyclovir or famciclovir, which are relatively affordable medications with few side effects, and to which the herpes virus rarely becomes resistant. These drugs are effective in preventing the recurrence of disease and in curbing the transmission of HSV-2 from infected to uninfected partners5.

2. In 2001, an international workshop organised by WHO, UNAIDS and LSHTM called for randomised controlled trials of HSV-2 therapy to definitely establish a causal relationship between HSV-2 and HIV-1 infectivity and acquisition6. We have now completed the first two randomised placebo-controlled trials of herpes suppressive treatment (with valacyclovir at a dose of 500 mg twice daily for 3 months) among HIV-infected individuals. The studies were conducted in Burkina Faso among women who were dually seropositive for HIV and HSV-2. In the first trial (ANRS1285a) published in today’s issue of the New England Journal of Medicine7, we report on the impact of HSV suppressive treatment on plasma and genital HIV-1 levels among women who did not require ART and who did not require a treatment for their HSV infection (they had less than 6 episodes per year). In the companion trial (ANRS1285b), which has been published recently in AIDS8, we reported the impact of herpes suppressive therapy on plasma and genital HIV-1 levels among women who were taking highly active antiretroviral therapy (HAART).

The ANRS 1285b trial was conducted among 60 women who had been taking HAART for at least 4 months. This trial showed that valacyclovir had an additional impact on the residual shedding of HIV-1 despite good systemic control of the virus.

This supports an effect of HSV-2 on independent mucosal HIV-1 replication - an important contribution to the HSV/HIV co-activation hypothesis.

Note on funding and sponsorship

This research was sponsored by France’s Agence Nationale de Recherches sur le Sida et les Hepatites (ANRS), with supplementary financial support from the United Kingdom’s Department for International Development (DFID).

The ANRS, created in 1992 to specifically respond to the many scientific challenges posed by the extension of the HIV/AIDS pandemic, coordinates research activities that span several disciplines from fundamental research, to clinical research, public health and socio-anthropological research.

DFID has been funding research on HIV/AIDS through a series of research programmes formerly called ‘Knowledge Programmes’ and currently ‘Research Programme Consortia’. The purpose of the current LSHTM-based Consortium on Sexual and Reproductive Health and HIV is to strengthen the evidence base to enable policy makers to identify and prioritise interventions that will improve reproductive and sexual health and reduce HIV incidence among economically poor populations in Africa and Asia; and to ensure that the research results are made available to policy makers at national and international levels in an intelligible and relevant form.

Posted by toshko under Herpes News | Comments (0)

NanoBio(R) Corporation Initiates Phase 2b Clinical Trial for Herpes Labialis Treatment

February 21, 2007

ANN ARBOR, Mich., Feb. 15 /PRNewswire/ — NanoBio(R) Corporation, a biopharmaceutical company developing novel products for the treatment and prevention of topical infections, today announced that it has begun enrolling patients in its Phase 2b study of NB-001, a drug candidate for the topical treatment of Herpes labialis. The Phase 2b trial is a randomized, placebo- controlled study at 30 sites in the United States, where 1,000 potential subjects are being recruited.

“We are pleased to be able to move NB-001 into the next stage of clinical development,” stated Dr. James Baker, NanoBio’s Chairman of the Board and Chief Science Officer. “Given the remarkable safety profile of NB-001 and the clear efficacy demonstrated in our prior trial, we are now able to perform a Phase 2b study with doses that are three and five times higher then previously used.”

Dr. Baker added, “NB-001 safely and effectively targets the Herpes virus when applied to the skin, thus making it a promising topical treatment for Herpes labialis. Its novel mechanism of action leaves little risk of drug resistance, which is a concern with the systemic anti-viral therapies used to treat this disease. These attributes may eventually allow NB-001 to be sold without a prescription.”

Summary of NanoBio’s Previous Clinical Studies for NB001

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

In 2005, NanoBio completed a Phase 2 study of NB-001 for the treatment of Herpes labialis. The trial was a multi-center, randomized, placebo-controlled study in the United States, involving 332 subjects. When compared to a placebo, a substantially higher proportion of subjects receiving NB-001 healed within three days (17% vs 2%, p=0.0046) or four days (25% vs. 10%, p=0.036). Also, the time it took for sores to heal in NB-001-treated subjects was shortened by over a day (6.26 days treated vs. 7.42 days untreated). No drug- related adverse events, no skin irritation, and no systemic absorption of NB- 001 were observed.

About NanoBio Corporation

NanoBio(R) Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates for the treatment of Herpes labialis (cold sores) and onychomycosis (nail fungus) are in clinical trials. In addition, preclinical work is ongoing for a treatment for methicillin resistant Staphylococcus aureus (MRSA), and mucosal vaccines for influenza and Hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Posted by toshko under Herpes News | Comments (0)

GlaxoSmithKline to Seek Injunction Against Ranbaxy Over Herpes Treatment

February 19, 2007

GlaxoSmithKline (GSK) (NYSE:GSK) says it will apply for a preliminary injunction to prohibit the launch of a generic version of its drug Valtrex (valacyclovir) used to treat herpes.

Internet Pharmacy - Buy Pharmacy at reasanoble prices.Internet Pharmacy provides confortable and easy way to order pharmacy via internet.

Ranbaxy Pharmaceuticals in Princeton recently received approval from the Food and Drug Administration to market generic valacyclovir.

In 2003, London-based GSK filed a patent infringement suit in U.S. District Court in New Jersey against Ranbaxy, alleging that the generic infringed on GSK’s patent for Valtrex, which expires in 2009.

Posted by toshko under Herpes News | Comments (0)

Valentine’s Day is like herpes - cheeky card

February 14, 2007

Paris - “Valentine’s Day sucks” and “I love you blah blah blah hearts n’ flowers yadda yadda yadda” are just some of the caustic anti-Valentine’s Day cards available free of charge on the Internet this week.

“Valentine’s Day is like herpes: just when you think it’s gone for good, it rears its ugly head once more. No wonder some people prefer to call it VD,” according to “Be My Anti-Valentine” on www.meish.org/vd.

The site offers around 40 cards for free emailing to recipients. The most frequently sent card boasts a flying Cupid with the words “Fat. Naked. Dangerous.” printed below.

There’s also “You’re chucked”, “At least my cat loves me” and “Oh, is there something special about today? I hadn’t noticed.”

Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The idea behind the anti-VD cards, says the site’s frequently asked questions page, is “to provide an alternative card-sending service for all the people who think Valentine’s Day is sickly-sweet, exclusively coupley, consumerist nonsense or
otherwise a bit naff”.

The original cards were created back in 2001 by Meg Pickard and David Pannett, then both single, working in new media and sharing a flat in London.

“I’m not anti-love or anti-romance or anti-relationships,” Pickard said on the site. “I’m against hollow gestures prescribed by people who are out to make money.”

By 2003, 30 000 cards were sent in two weeks, and in 2005 the number of cards soared past the 200 000 mark before the server collapsed under the strain.

On Tuesday it was impossible to download a card. - Sapa-AFP

Posted by toshko under Herpes News | Comments (0)

NIH Funds Further Clinical Development of VivaGel

February 13, 2007

Starpharma Holdings Limited (ASX:SPL,USOTC:SPHRY) today signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Child Health and Human Development (NICHD) of the US National Institutes of Health (NIH), to provide funding of a further clinical trial of VivaGelâ„¢ in sexually active women.

This further support from the NIH is non-dilutive for shareholders, and, like other NIH funding to date, has no negative impact on the commercial returns that Starpharma will receive from VivaGelâ„¢. This support is in addition to the previously announced US$20.3 million (A$26m) funding provided by the NIH to support the development of VivaGelâ„¢ for the prevention of HIV, and the funding of the clinical study related to VivaGelâ„¢ for the prevention of genital herpes.

“This is exciting news. The clinical study will complement the ongoing development activities being conducted under a range of NIH funded mechanisms for the development of VivaGel™ for prevention of HIV and genital herpes, and further consolidates the company’s important relationship with the NIH,� said Dr Jackie Fairley, Chief Executive Officer of Starpharma.

The trial will be conducted by The Microbicide Trials Network (MTN), a worldwide collaborative clinical trials network established by Division of AIDS (DAIDS) of the NIAID to evaluate the safety and efficacy of microbicides. The trial will be sponsored by NIAID and NICHD, and co-sponsored by Starpharma. The study will be conducted at two sites in the United States: University of South Florida, Tampa, Florida and University of Puerto Rico, San Juan, Puerto Rico. The study is expected to commence in the second quarter of 2007. VivaGelâ„¢ is under development for the prevention of HIV and genital herpes.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

About Starpharma:
Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL’s dendrimer technology are already
on the market in the form of diagnostic elements and laboratory reagents. The Company’s lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting
groups are added to allow location of specific cell type, such as cancer cells). More broadly the company is actively exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

Dendrimers: A type of precisely-defined, branched nanoparticle. Dendrimers have applications in themedical, electronics, chemicals and materials industries.

Microbicides: A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

American Depositary Receipts (ADRs): Starpharma’s ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

Posted by toshko under Herpes News | Comments (0)

Six More Schools Report Cases Of Herpes Infection In Wrestlers

February 8, 2007

St. Paul, MN (AHN) - After an eight-day ban on practice and competition last week due to the infection, six more schools in Minnesota have reported cases of herpes among high school wrestlers. Earlier, 16 wrestlers were diagnosed with herpes within the Minnesota State High School League and so far, 16 teams and 40 wrestlers have reported infections of the skin-to-skin virus.

Symptoms have included lesions on the face, head and neck of wrestlers. The wrestling teams were scheduled to resume practices and matches Wednesday.

AP quotes Craig Perry, associate director at the league who oversees wrestling as saying, “You can never say there’s no more risk, but the suspension is done. It accomplished what it was intended to accomplish. … We’ve been able to isolate those cases that come out of this. It helped us and it helped our programs.”

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

The authorities are still investigating the source of the outbreak and are speculating it might have originated with wrestlers from Valentine High School in Nebraska who had competed in a meet in Rochester. However, the Nebraska wrestlers, when evaluated showed no evidence of herpes.

Herpes gladiatorum is a kind of herpes most commonly occurring among wrestlers, judo players or other athletes who have with very close skin contact with each other. It is a serious kind of herpes and, just like any other form of herpes, is contracted through physical contact. Catching this infection can be a major problem for an athlete because he might get disqualified from not only competition but also training, even though he cannot be blamed since he contracted it unknowingly from someone else.

Posted by toshko under Herpes News | Comments (0)

GlaxoSmithKline to Seek Injunction Against Ranbaxy Over Herpes Treatment

February 5, 2007

GlaxoSmithKline (GSK) (NYSE:GSK) says it will apply for a preliminary injunction to prohibit the launch of a generic version of its drug Valtrex (valacyclovir) used to treat herpes. Ranbaxy Pharmaceuticals in Princeton recently received approval from the Food and Drug Administration to market generic valacyclovir.

Drugs Online - Buy Drugs Online at reasanoble prices.DrugOnline.cc provides confortable and easy way to order drugs online including drugs free shipping.

In 2003, London-based GSK filed a patent infringement suit in U.S. District Court in New Jersey against Ranbaxy, alleging that the generic infringed on GSK’s patent for Valtrex, which expires in 2009.

Posted by toshko under Herpes News | Comments (0)

Researchers Test Herpes as Brain Cancer Treatment

February 2, 2007

Glioma is the most common form of brain cancer, and most of its victims are adults in the prime of their life.

There has never been a successful treatment for the deadly brain disease, but doctors at Methodist Hospital in Houston believe they have finally found a cure. The hospital is one of the only medical centers in the country using the treatment.

One patient using the new treatment is Connie Radford. She has spent the past 20 years as a Houston-area school teacher, and while she had to step away from the job she loves for cancer treatment, she plans to get back to her students soon.

“I think I’m like your average school teacher. I want to work hard and work smart, do the right thing and leave a legacy for my kids. In this case, my students,” Radford told FOX 26’s Melissa Wilson.

Radford is taking part in a study that uses herpes as a brain cancer treatment.

Discount Pharmacy - Buy Pharmacy at discount prices including free shipping.Discount Pharmacy provides confortable and easy way to order discount pharmacy online.

Doctors say they believe herpes is a possible cure for glioma because it infiltrates the brain well.

Dr. New at Methodist Hospital is the principal investigator in the study. She explains doctors can use herpes, or the common cold virus, as a “cargo ship” to carry a herpes virus gene into a patient’s tumor.

To carry out the unique procedure, a neurosurgeon injects the virus into the brain tumor during surgery. After which, the patient takes Valtrex, the oral medication that treats herpes. Valtrex kills off the virus, and as the herpes virus dies, it is also blasts the cancer cells, making them self-destruct.

As part of Radford’s treatment, she also completed chemotherapy and continues to undergo radiation.

“I feel great. I have no side effects, no headaches. I occasionally take a Tylenol, but that’s a pretty phenomenal thing,” said Radford.

Doctors say it’s still too early to tell what Radford’s outcome will be, but it’s giving the teacher the hope she needs. She knows she’s just a patient in a study, but she’s confident by participating in it, it will help others in the future.

Posted by toshko under Herpes News | Comments (0)